The Beauty Health Company (NASDAQ:SKIN) Receives Average Recommendation of “Reduce” from Brokerages

The Beauty Health Company (NASDAQ:SKINGet Free Report) has received a consensus recommendation of “Reduce” from the twelve ratings firms that are presently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and two have issued a buy recommendation on the company. The average 12 month target price among brokers that have covered the stock in the last year is $6.29.

SKIN has been the subject of several research analyst reports. TD Cowen lowered their target price on Beauty Health from $4.00 to $3.00 and set a “hold” rating for the company in a research note on Monday, May 13th. Canaccord Genuity Group upped their target price on Beauty Health from $3.00 to $4.00 and gave the company a “hold” rating in a report on Thursday, March 14th. Piper Sandler reduced their target price on Beauty Health from $3.00 to $2.50 and set an “underweight” rating on the stock in a report on Friday, May 10th. Stifel Nicolaus reiterated a “hold” rating and issued a $4.00 target price (up from $3.00) on shares of Beauty Health in a report on Wednesday, March 13th. Finally, DA Davidson reiterated a “buy” rating and issued a $5.00 target price on shares of Beauty Health in a report on Monday, May 13th.

Check Out Our Latest Stock Report on SKIN

Beauty Health Stock Down 0.5 %

SKIN stock opened at $1.95 on Friday. The company has a market cap of $241.08 million, a PE ratio of -2.79 and a beta of 0.96. The business has a 50-day simple moving average of $2.42 and a 200 day simple moving average of $3.00. Beauty Health has a 52 week low of $1.35 and a 52 week high of $8.96. The company has a quick ratio of 5.55, a current ratio of 6.57 and a debt-to-equity ratio of 10.51.

Beauty Health (NASDAQ:SKINGet Free Report) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.04. The business had revenue of $81.40 million during the quarter, compared to the consensus estimate of $80.56 million. Beauty Health had a negative return on equity of 0.02% and a negative net margin of 20.48%. Beauty Health’s revenue for the quarter was down 5.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.17) earnings per share. Sell-side analysts anticipate that Beauty Health will post -0.07 EPS for the current fiscal year.

Hedge Funds Weigh In On Beauty Health

A number of institutional investors have recently modified their holdings of the company. Jacobs Levy Equity Management Inc. acquired a new position in shares of Beauty Health during the first quarter worth approximately $4,297,000. Bayesian Capital Management LP acquired a new position in shares of Beauty Health during the first quarter worth approximately $521,000. Price T Rowe Associates Inc. MD raised its position in shares of Beauty Health by 8.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 75,281 shares of the company’s stock worth $335,000 after purchasing an additional 5,934 shares during the period. SageView Advisory Group LLC acquired a new position in shares of Beauty Health during the first quarter worth approximately $60,000. Finally, Russell Investments Group Ltd. purchased a new stake in Beauty Health in the 1st quarter valued at $279,000. 93.26% of the stock is owned by institutional investors and hedge funds.

About Beauty Health

(Get Free Report

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.

Featured Stories

Analyst Recommendations for Beauty Health (NASDAQ:SKIN)

Receive News & Ratings for Beauty Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beauty Health and related companies with MarketBeat.com's FREE daily email newsletter.